The first-generation epidermal growth factor receptor (EGFR) inhibitor erlotinib is approved by the FDA for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (4). Here, EGFR is linked to non-small cell lung carcinoma.